Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: End Stage Liver DIsease Clear all
Terminated Phase 3 Interventional Results available

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

NCT03702920
View directory record Official record
Conditions
Acute-On-Chronic Liver Failure
Interventions
SMT + PE-A 5%, Standard Medical Treatment
Biological · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
18 Years to 79 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Coronado, California • Los Angeles, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 2:59 AM EDT
Terminated Phase 2 Interventional

HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection

NCT00228592
View directory record Official record
Conditions
Hepatitis B, Liver Transplantation
Interventions
HepeX-B, Hepatitis B Immune Globulin (HBIg)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Rochester, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2007 · Synced Jul 22, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge

NCT04351880
View directory record Official record
Conditions
Heart Failure, Copd, Liver Failure, Diabetes Mellitus, Cancer, End Stage Renal Disease
Interventions
Medically Tailored Meals
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Denver, Colorado • Lafayette, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Jul 22, 2026, 2:59 AM EDT
Not listed No phase listed Observational

Developing Prediction Models for Allograft Failure After Liver Transplantation

NCT05289609
View directory record Official record
Conditions
Liver Transplant Disorder
Interventions
Liver Transplantation
Procedure
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Jacksonville, Florida • Worcester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Jul 22, 2026, 2:59 AM EDT
Completed Phase 1 Interventional Results available

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

NCT03934736
View directory record Official record
Conditions
End Stage Renal Disease on Hemodialysis (Diagnosis)
Interventions
HEPLISAV-B®
Drug
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jul 22, 2026, 2:59 AM EDT
Completed No phase listed Observational

Psychosocial Risks in Liver Transplant Recipients

NCT02826460
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 74 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Jul 22, 2026, 2:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors

NCT03803423
View directory record Official record
Conditions
End Stage Renal Disease, End Stage Liver Disease
Interventions
The Donor App
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
6
States / cities
San Diego, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 22, 2026, 2:59 AM EDT
Completed Not applicable Interventional

End Stage Liver Disease and Body Composition Assessment: Utilizing Bioelectric Impedance Analysis (BIA)

NCT00374582
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Bodystat Quadscan 4000, bodystat quadscan 400
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2011 · Synced Jul 22, 2026, 2:59 AM EDT
Completed No phase listed Observational

Transplant Patient Registry of Liver, Kidney and/or Pancreas

NCT00238693
View directory record Official record
Conditions
End Stage Renal Disease, End Stage Liver Disease
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Not listed
Enrollment
13,767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Jul 22, 2026, 2:59 AM EDT
Not listed Phase 1 Interventional

Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease

NCT01711073
View directory record Official record
Conditions
End Stage Liver DIsease
Interventions
Mobilization with G-CSF and Mozobil
Drug
Lead sponsor
Proteonomix, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Jul 22, 2026, 2:59 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol

NCT00678834
View directory record Official record
Conditions
End Stage Cardiac Failure, Pulmonary Failure, End Stage Liver Disease, Morbid Obesity, Recalcitrant Epilepsy Requiring Surgery, Healthy Subjects
Interventions
To surgery patients, Tocopherol capsules., Tocotrienol to healthy subjects., To surgery patients, Tocotrienol capsules.
Dietary Supplement
Lead sponsor
Chandan K Sen
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Jul 22, 2026, 2:59 AM EDT
Completed Phase 4 Interventional

A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

NCT02864199
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
12
States / cities
Birmingham, Alabama • Kansas City, Kansas • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Jul 22, 2026, 2:59 AM EDT
Recruiting Not applicable Interventional

Adverse Outcomes and Mortality in Liver Transplant

NCT05477277
View directory record Official record
Conditions
End Stage Liver DIsease, Sarcopenia, Sarcopenic Obesity, Cirrhosis
Interventions
MAsS
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jul 22, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Reducing Disparities in the Quality of Advance Care Planning for Older Adults

NCT03516994
View directory record Official record
Conditions
Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease, Interstitial Lung Disease, Amyotrophic Lateral Sclerosis, End Stage Liver Disease, End Stage Renal Disease, Diabetes Complications
Interventions
Respecting Choices First Steps, Five Wishes Form
Behavioral
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Jul 22, 2026, 2:59 AM EDT
Terminated Phase 2 Interventional

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

NCT06987968
View directory record Official record
Conditions
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
Interventions
VS-01 on top of SOC (Active Treatment Group), SOC
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 22, 2026, 2:59 AM EDT
Terminated Not applicable Interventional Results available

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

NCT03534141
View directory record Official record
Conditions
Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Interventions
Esophageal cooling/warming device, Mild hypothermia, Normothermia
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 22, 2026, 2:59 AM EDT
Completed No phase listed Observational

Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation

NCT01467011
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Enteric-coated Mycophenolate Sodium
Drug
Lead sponsor
R. Mark Ghobrial, MD
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Jul 22, 2026, 2:59 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Factors Associated With End Stage Liver Disease

NCT01846819
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Fatigue, Depression
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Jul 22, 2026, 2:59 AM EDT
Completed Not applicable Interventional Results available

Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)

NCT03540771
View directory record Official record
Conditions
End Stage Liver Disease, Decompensated Cirrhosis of Liver
Interventions
Palliative Care
Other
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 120 Years
Enrollment
1,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jul 22, 2026, 2:59 AM EDT
Terminated Not applicable Interventional

Safety Study of the Aethlon Hemopurifier

NCT02215902
View directory record Official record
Conditions
End Stage Renal Disease, Hepatitis C Infection
Interventions
Affinity plasmapheresis
Device
Lead sponsor
Aethlon Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Jul 22, 2026, 2:59 AM EDT
Completed No phase listed Observational

Adult-to-Adult Living Donor Transplant Cohort Study

NCT01619475
View directory record Official record
Conditions
Liver Diseases, Hepatocellular Cancer, End Stage Liver Disease, Hepatitis C, Liver Cirrhosis
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
18 Years and older
Enrollment
1,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Jul 22, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Prehabilitation Intervention to Maximize Early Recovery (PRIMER) in Liver Transplantation

NCT03584646
View directory record Official record
Conditions
Liver Diseases, End Stage Liver Disease, Frailty
Interventions
Nokia GO Wearable StepTracker, Medication Reminder, Weekly Check-in appointment with study team or provider
Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Jul 22, 2026, 2:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

Immune Tolerance Induction After Liver Transplantation

NCT07269041
View directory record Official record
Conditions
Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders, End Stage Liver Disease
Interventions
Donor Hematopoietic Stem and Progenitor Cell Infusion
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 22, 2026, 2:59 AM EDT
Not listed No phase listed Observational

Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease

NCT06014320
View directory record Official record
Conditions
Liver Cirrhosis, Hemophilia, Hemophilia A, Hemophilia B, Liver Transplant Disorder, Liver Failure, Coagulation Factor Deficiency
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Jul 22, 2026, 2:59 AM EDT